IRIS
NECCHI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.763
NA - Nord America 3.266
EU - Europa 2.708
SA - Sud America 2.099
AF - Africa 125
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
Totale 13.982
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.087
SG - Singapore 2.363
BR - Brasile 1.750
CN - Cina 1.419
HK - Hong Kong 1.016
SE - Svezia 917
VN - Vietnam 512
DE - Germania 319
IT - Italia 317
RU - Federazione Russa 306
RO - Romania 266
AR - Argentina 139
FI - Finlandia 119
IN - India 110
AT - Austria 107
GB - Regno Unito 103
CA - Canada 78
BD - Bangladesh 71
MX - Messico 68
PL - Polonia 55
EC - Ecuador 53
ZA - Sudafrica 51
ID - Indonesia 48
JP - Giappone 42
NL - Olanda 41
IQ - Iraq 40
FR - Francia 38
CO - Colombia 36
IE - Irlanda 33
ES - Italia 29
TR - Turchia 29
PY - Paraguay 28
VE - Venezuela 26
CL - Cile 21
PE - Perù 19
MA - Marocco 17
PK - Pakistan 17
UA - Ucraina 17
UY - Uruguay 16
UZ - Uzbekistan 15
LT - Lituania 12
EG - Egitto 11
KE - Kenya 11
AZ - Azerbaigian 10
AU - Australia 9
TN - Tunisia 9
EU - Europa 8
IR - Iran 8
NI - Nicaragua 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
JO - Giordania 6
LB - Libano 6
NG - Nigeria 6
BE - Belgio 5
DZ - Algeria 5
KW - Kuwait 5
KZ - Kazakistan 5
PA - Panama 5
SN - Senegal 5
BG - Bulgaria 4
BH - Bahrain 4
IL - Israele 4
JM - Giamaica 4
MY - Malesia 4
NP - Nepal 4
AL - Albania 3
BB - Barbados 3
CI - Costa d'Avorio 3
GR - Grecia 3
GY - Guiana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GT - Guatemala 2
KG - Kirghizistan 2
KH - Cambogia 2
KR - Corea 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LY - Libia 1
NZ - Nuova Zelanda 1
OM - Oman 1
Totale 13.979
Salva come PNG Salva come JPEG
Città #
Singapore 1.024
Hong Kong 1.012
Dallas 561
Shanghai 407
Ashburn 399
Hefei 344
Lawrence 302
Princeton 302
Ho Chi Minh City 218
Moscow 183
New York 176
Beijing 166
São Paulo 155
Hanoi 111
Nuremberg 110
Los Angeles 109
Milan 98
Boardman 96
Helsinki 69
Rio de Janeiro 65
Munich 60
Rome 42
Vienna 41
Warsaw 40
Belo Horizonte 37
Tokyo 37
Montreal 36
Turku 36
Brasília 34
Dublin 32
Brooklyn 29
Orem 28
Denver 26
Poplar 26
Porto Alegre 26
Santa Clara 25
Phoenix 24
Campinas 23
Houston 23
Johannesburg 23
Haiphong 22
Pune 22
Salvador 22
London 21
Atlanta 20
Stockholm 20
Curitiba 19
Da Nang 19
Frankfurt am Main 19
Mexico City 19
Mumbai 19
Biên Hòa 17
Caxias do Sul 17
Chicago 17
Guangzhou 17
Chennai 16
Recife 16
Columbus 15
Council Bluffs 15
Sorocaba 15
Turin 15
Baghdad 14
Bogotá 14
Dhaka 14
Fortaleza 14
Guayaquil 14
Manaus 14
Quito 14
Seattle 14
Tashkent 14
Toronto 14
Lappeenranta 13
Ribeirão Preto 13
The Dalles 13
Amsterdam 12
Ankara 12
Buenos Aires 12
Charlotte 12
Goiânia 12
Guarulhos 12
Hải Dương 12
Manchester 12
Montevideo 12
Osasco 12
Thái Bình 12
Carapicuíba 11
Kassel 11
Lima 11
Nairobi 11
Querétaro 11
Ribeirão das Neves 11
Santo André 11
Asunción 10
Cesano Boscone 10
Hanover 10
Tianjin 10
Washington 10
Baku 9
Boston 9
Can Tho 9
Totale 7.402
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 325
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 163
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 112
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 104
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 89
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 87
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 84
A global approach to improving penile cancer care 84
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review 79
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis 78
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 77
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies 77
Causal contributors to tissue stiffness and clinical relevance in urology 76
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 75
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings 75
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 74
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 73
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 73
Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence 72
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 72
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 72
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 72
Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy 72
A risk calculator predicting recurrence in lymph node metastatic penile cancer 71
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 71
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 69
The obesity paradox in metastatic castration-resistant prostate cancer 68
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation 67
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis 67
Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action 67
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 67
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGF beta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial 67
Pulmonary lesion after surgery for renal cancer: progression or new primary? 66
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 66
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 65
[The treatment of early-stage germ cell tumors of the testis (GCTT)]. [Il trattamento dei Tumori Germinali del Testicolo (TGT) in fase iniziale.] 65
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 65
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 64
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial 64
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma 63
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 63
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients 62
Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients 62
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 61
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 61
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 60
A Plea for Economically Sustainable Evidence-based Guidelines 60
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration 59
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 59
Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians 58
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 58
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 58
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 58
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 57
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 57
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty 56
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities 56
Penile cancer 56
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 56
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 55
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 55
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 55
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma 54
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 53
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus 53
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 53
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer 53
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 52
Penile cancer 51
Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer 51
Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery 50
Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database 50
Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation 50
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis 49
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent 49
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 49
The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification 49
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression 48
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure 48
Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy 48
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 48
Primary Renal Tumour Response to Immunotherapy: Lessons from Metastatic Disease and Insights into Earlier Settings 48
Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients 47
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors 47
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial 47
Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease 46
Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision 46
Revolutionizing care for rare genitourinary tumours 46
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database 46
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study 46
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 45
UltraPulse Carbon Dioxide Laser Plus Methyl Aminolevulinate-Photodynamic Therapy for the Treatment of Penile Cancer 45
EARLY AND LATE HEAT-SHOCK PROTEINS IN WHEATS AND OTHER CEREAL SPECIES 44
Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes 44
Funcion sparing surgery in uro-oncology: germ cell tumors of the testis [La chirurgia "function sparing" in urologia oncologica: tumori germinali del testicolo (TGT)] 44
Understanding the somatic-type malignant differentiation in male germ-cell cancer: A work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 2008;26:595-9 44
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees 44
Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy 44
Targetable gene fusions and aberrations in genitourinary oncology 44
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up 43
Totale 6.397
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.590
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.590
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202162 0 0 0 0 0 19 39 0 4 0 0 0
2021/2022270 0 53 3 101 1 8 13 10 13 11 4 53
2022/20231.668 675 354 123 38 18 233 47 94 48 5 15 18
2023/2024934 23 57 65 63 79 182 132 118 7 20 44 144
2024/20254.910 602 94 75 78 84 350 861 490 861 739 292 384
2025/20266.349 1.026 1.134 972 1.997 967 253 0 0 0 0 0 0
Totale 14.384